<DOC>
	<DOC>NCT01093534</DOC>
	<brief_summary>The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.</brief_summary>
	<brief_title>Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.</brief_title>
	<detailed_description>Participants satisfying all selection criteria at the end of the 2-week, single blind, placebo run-in period were randomized to receive 12-week double-blind treatment with solifenacin 5 mg or 10 mg once daily, or placebo.</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Symptoms of overactive bladder (OAB), including urinary frequency, urgency or urge incontinence, for greater than or equal to 3 months Urodynamic diagnosis of detrusor overactivity (DO) Either na√Øve to antimuscarinic treatment (i.e. no prior history of use of antimuscarinic agents) or 6months antimuscarinic treatment free (i.e. have had no antimuscarinic treatment within 6 months) prior to the screening visit Bladder postvoid residual volume of less than 30 ml Available to complete the study History of stress urinary incontinence, urethral sphincter incompetence or neurogenic detrusor overactivity History, signs or symptoms suggestive of urinary tract infection (confirmed by positive urine analysis), obstruction or urogenital prolapse (greater than grade II) History of urinary tract operation within 6 months prior to screening Indwelling catheter or permanent catheter fitted History of pelvic area radiotherapy treatment Uncontrolled diabetes mellitus History of fibromyalgia Postpartum or breastfeeding within 3 months prior to screening visit Either pregnant or intends to become pregnant during the study or sexually active, of childbearing potential and is unwilling to utilize a reliable method of birth control (note: reliable methods are contraceptive pills of combination type, hormonal implants or injectable contraceptives) Positive prestudy hepatitis B surface antigen, hepatitis C antibody or human immunodeficiency virus (HIV) result at time of screening History of drug and / or alcohol abuse at time of screening History of urinary retention, severe gastrointestinal obstruction (including paralytic ileus or intestinal atony or toxic megacolon or severe ulcerative colitis), myasthenia gravis, uncontrolled narrow angle glaucoma or shallow anterior chamber or deemed to be at risk for these conditions Undergoing hemodialysis or has severe renal impairment or moderate hepatic impairment or who are on treatment with a potent cytochrome p450 (CYP) 3A4 inhibitor, e.g. Ketoconazole Currently dosing with medication(s) intended to treat overactive bladder symptoms or has a history of nondrug treatment, such as electrical therapy, magnetic field stimulation, pelvic floor treatment or bladder training intended to treat overactive bladder symptoms within 6 months prior to screening, as described in the list of prohibited medications Currently receiving or has a history of treatment with alpha blockers, botulinum toxin (cosmetic use is acceptable), resiniferatoxin or pelvic floor muscle relaxants within 9 months prior to screening Participated in any clinical study less than or equal to 3 months prior to screening</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Vesicare</keyword>
	<keyword>Solifenacin</keyword>
	<keyword>Detrusor Overactivity</keyword>
	<keyword>Urinary Nerve Growth Factor</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Bladder wall thickness</keyword>
</DOC>